Skip to main content


Table 1 BACE1 knockout mouse phenotypes

From: BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease

Phenotype Putative Substrate References
Astrogenesis increase; neurogenesis decrease Jag1 [46]
Axon guidance defects CHL1 [36]-[38]
Hyperactivity NRG1 [29],[48]
Hypomyelination NRG1 [39]-[41]
Memory deficits Unknown [17],[30],[32],[42],[43]
Insulin sensitivity enhanced Unknown [29],[51],[52]
Muscle spindle reduction NRG1 [44]
Neurochemical deficits Unknown [45]
Neurodegeneration with age Unknown [47]
Postnatal lethality, growth retardation Unknown [29]
Retinal abnormalities VEGFR1 [49]
Schizophrenia endophenotypes NRG1 [48]
Seizures Navβ2 [42],[47],[50],[53]
Spine density reduction NRG1 [48]
BACE2 knockout mouse phenotypes
Phenotype Putative Substrate References
Normal --- [29]
Pancreatic β cell increase Tmem27 [54]
Pigmentation abnormalities PMEL [55]
BACE1/2 double knockout mouse phenotypes
Phenotype References
Similar to BACE1 knockout, except postnatal lethality is enhanced [29]